US · Healthcare · Biotechnology
EPS came in at -0.09 against a street estimate of -0.11 — a beat of 18.2%.
Analysts rate CytomX Therapeutics Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $12.25.
| Fund | Stake |
|---|---|
| FMR Inc | 14.67% |
| Kynam Capital Management, LP | 9.96% |
| Bank of America Corp | 4.68% |
| Perceptive Advisors LLC | 4.63% |
| VR Adviser, LLC | 4.58% |
| Vanguard Capital Management, LLC | 4.01% |
| Point72 Asset Management, L.P. | 3.61% |
| State Street Corp | 2.60% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CYTOMX THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $17.2 million cash and equivalents; $313.1 million short-term i | 2026-08-06 |
| Results announced · Q3 2026 CYTOMX THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $330.3 million as of June 30, 2026 | 2026-08-06 |
| Board / officer change · Q3 2026 CYTOMX THERAPEUTICS, INC. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Charles Fuchs, M.D., M.P.H., appointed to Board of Directors effective July | 2026-07-27 |
| Board / officer change · Q2 2026 CYTOMX THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of record date (April 20, 2026): 217,702,919 common shares • Shares | 2026-06-22 |
| Material agreement · Q2 2026 CYTOMX THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company received $37.0 million in aggregate target nomination payments from Regeneron for | 2026-06-03 |
| Quarterly report · Q1 2026 CYTOMX THERAPEUTICS, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position strengthened significantly: Cash and equivalents rose to $28.8 m | 2026-05-07 |
| Proxy statement · Q2 2026 CYTOMX THERAPEUTICS, INC. – 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two directors with terms expiring at 2029 Annual | 2026-04-30 |
| Annual report FY2025 CYTOMX THERAPEUTICS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Clinical-stage oncology biopharmaceutical company, trades | 2026-03-16 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CytomX Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.